Navigation Links
CHOP expert Dr. Garrett Brodeur honored for career work in neuroblastoma

The Advances in Neuroblastoma Research Association (ANRA) is conferring its highest honor on pediatric oncologist Garrett M. Brodeur, M.D., of the Cancer Center at The Children's Hospital of Philadelphia (CHOP). Brodeur will receive the ANRA Lifetime Achievement Award tomorrow at the association's international meeting in Cologne, Germany.

The Award singles out a researcher who has achieved worldwide scientific prominence in investigating neuroblastoma over the course of a career. Neuroblastoma is the most common solid tumor of childhood.

A cancer of the peripheral nervous system that typically appears as a tumor in a child's abdomen or chest, neuroblastoma varies greatly in severity, ranging from forms that spontaneously disappear to high-risk subtypes that are difficult to cure. Because of this variability, researchers have sought ways to predict the course of disease in order to select the most appropriate treatment for each patient.

Over his career, Brodeur has focused on identifying the genes, proteins and biological pathways that give rise to neuroblastoma and drive its clinical behavior. He also has built on this knowledge to develop more effective and less toxic treatments for children.

He first demonstrated in the 1980s that some neuroblastoma cells developed multiple copies of the MYCN gene, and this identified a high-risk subtype of neuroblastoma, necessitating more aggressive treatment. This discovery ushered in the current era of genomic analysis of tumors, both in adult and pediatric oncology. Profiling specific molecular alterations in a given patient's tumor helps guide oncologists toward the most appropriate treatment.

Brodeur and colleagues also discovered important neuroblastoma-related genetic changes, such as deletion of the short arm of chromosome 1 and loss of the CHD5 tumor suppressor gene. He collaborated with other CHOP researchers who identified the ALK gene as the gene responsible for most cases of hereditary neuroblastoma.

Another major focus of his research has been on the role of TRK receptor tyrosine kinases, a family of signaling proteins that control the clinical behavior of neuroblastomas. His preclinical work led to a clinical trial with a novel drug that selectively blocks these signals. He is now working on the second generation of such drugs, as well as on nanoparticle delivery systems to treat patients more effectively, and with less toxicity.

Brodeur has been a member of the CHOP medical staff since 1993 and holds the Audrey E. Evans Endowed Chair in Pediatric Oncology at the Hospital. He also is a professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania, where he is an associate director of the Abramson Cancer Center. Last year, Brodeur received the prestigious Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO).

This is only the third time that ANRA has presented the Lifetime Achievement Award. It first honored Dr. Audrey E. Evans in 2000. Evans, now retired, did pioneering research on neuroblastoma at The Children's Hospital of Philadelphia and hosted the original Advances in Neuroblastoma Research meetings at CHOP, beginning in 1975. In 2012, ANRA honored Dr. Manfred Schwab of the German Cancer Research Center in Heidelberg, who first identified the MYCN oncogene in neuroblastoma.


Contact: Ashley Moore
Children's Hospital of Philadelphia

Related biology news :

1. Worlds leading coral experts to gather in Australia
2. SDSCs big data expertise aiding genomics research
3. Monarch butterflies down again this year as decline continues, says Texas A&M expert
4. Smell and taste experts to discuss new discoveries
5. Agricultural expert outlines path for developing nations to double food production, meet 2050 demand
6. Center for North Sea oil expertise set to boost jobs and growth
7. Coral reef experts to present latest coral reef science during July symposium
8. Divide the Antarctic to protect native species, propose experts
9. World experts meet in Edinburgh to consider how life experiences impact on our genes
10. Mining cleanup benefits from Texas A&M expertise
11. Stanford expert brings climate change science to heated Capitol Hill
Post Your Comments:
Related Image:
CHOP expert Dr. Garrett Brodeur honored for career work in neuroblastoma
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: